Beta

Filana therapeutics, inc.FLNA.US Overview

US StockHealthcare
(No presentation for FLNA)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

FLNA AI Insights

FLNA Overall Performance

FLNA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

FLNA Recent Performance

-

Filana therapeutics, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

FLNA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check FLNA's Trend

FLNA Key Information

FLNA Valuation Metrics

FLNA Profile

Price of FLNA

FLNA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

FLNA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.48
PE Ratio (TTM)
-
Forward PE
151.52
PS Ratio (TTM)
2.54
PB Ratio
1.05
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.48
PE Ratio (TTM)
-
Forward PE
151.52
PS Ratio (TTM)
2.54
PB Ratio
1.05
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is FLNA's latest earnings report released?

    The most recent financial report for Filana therapeutics, inc. (FLNA) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating FLNA's short-term business performance and financial health. For the latest updates on FLNA's earnings releases, visit this page regularly.

  • How much cash does FLNA have?

    At the end of the period, Filana therapeutics, inc. (FLNA) held Total Cash and Cash Equivalents of 95.5M, accounting for 0.81 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • What are the PEG ratio and PE ratio of FLNA?

    The latest valuation data shows Filana therapeutics, inc. (FLNA) has a Price-To-Earnings (PE) ratio of -1.04 and a Price/Earnings-To-Growth (PEG) ratio of -0.11. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.